Parkinson’s patients ‘owed’ more research into using cancer drug as treatment

News

Author: AdminPublished: 2 November 2015

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

A small clinical trial showed that cancer drug Nilotinib may reverse late-stage Parkinson’s disease, potentially enabling participants to speak and walk again for the first time in years.

President and co-founder of The Cure Parkinson’s Trust, Tom Isaacs, has called for a close follow up of this small study to ensure that any opportunity for a breakthrough in the treatment of Parkinson’s is not missed.

Isaacs said: ‘Nilotinib is a case in point. When people with Parkinson’s volunteer for clinical trials and feel the type of marked improvements to their symptoms and wellbeing as those reported in this study, we owe it to them, and indeed everyone, to follow the results up as quickly and as rigorously as possible.”

Go Back

Share this story

Comments


Related articles


young onset parkinsons

Interviews

Crowdfunded Irish feature film shines light on young onset Parkinson’s

We spoke to writer and director Chiara Viale

READ MORE

Women and Parkinson's

Women and Parkinson’s: “Being pregnant was scary”

One woman’s poignant account of pregnancy and Parkinson’s

READ MORE

Interviews

Charity Miles: the app “changing the way you see the world”

We talk to the founder of the Charity Miles app

READ MORE